


Version Date 01/April/2010

David J. Portman, M.D.
**The Columbus Center for
Women's Health Research**

Portman Obstetrics and Gynecology Associates

99 North Brice Road Suite 120
Columbus, Ohio 43213

Columbus Center for
Women's Health Research
Phone (614) 861-6707
Fax (614) 861-6335
dportman@ccvhr.com

Portman Obstetrics
and Gynecology Associates
Phone (614) 864-4919
Fax (614) 864-4928
portmanobgyn@aol.com

PERSONAL

Director of a Clinical Research Center with research interests in contraception, menopause, sexual dysfunction, hormone replacement therapy, osteoporosis, and gynecologic endocrinology. Expertise in pelvic floor reconstructive surgery and female urinary incontinence. Lectures nationally and consults widely on medical and surgical issues pertaining to Women's Health. He sits on numerous advisory panels. Board-certified Obstetrician/Gynecologist. Maintains a private practice in ob/gyn.

EDUCATION

B.A. in History and Premedicine, Northwestern University, Evanston, Illinois, 1984
M.D. The Ohio State University College of Medicine, Columbus, 1990
OB/GYN Post-Graduate Residency, The Ohio State University Hospitals, Columbus, 1994

EMPLOYMENT

- 1997-Present *Principal Investigator and Director, The Columbus Center for Women's Health Research - An independent private research center dedicated to innovation in the medical treatment of women, participating in multi-center clinical trial and independent research*
- 1994-Present *Portman Obstetrics and Gynecology, Associates Private Practice*
- 1994-Present *Clinical Instructor, Department of OB/GYN Ohio State University Hospital and lecturer in the Department of Medical Humanities*
- 1995-2008 *Founder and President, Ob/Gyn Physician Services, Inc. - Provider of Obstetric and Gynecologic care for the under-insured and under-served of the East Columbus community.*
- 1995-2008 *Co-Director of Clinic Ob/Gyn Emergency Services Mt Carmel East Hospital-- Supervising resident and attending staff*
- 2003-2004 *Board Member, Pfizer National Women's Health Advisory Board*
- 2004-Present *Duramed Pharmaceuticals Council for the Advanced Treatment of Menopause*

2007-Present *American Medical Systems Advisory Board—Advise regarding pelvic floor surgery device design and implementation*

2007-2008 *Vice-Chairman, Mount Carmel East Hospital, Department of OB/Gyn*

2009-present *NAMS Abstract Review Committee*

RESEARCH and SOCIETIES

RESEARCH, PUBLICATIONS, PRESENTATIONS

The Columbus Center for Women's Health Research, 1997-Present

-- A double-blind, randomized, parallel study comparing 17-Beta estradiol TD 7-day patch 20, 40, 60 and 80 µg/day with placebo in the treatment of vasomotor symptoms in postmenopausal women.

-- An open-label, non-comparative, multicenter study to evaluate contraceptive efficacy, cycle control and safety of a one-compartment all-EVA vaginal ring.

-- A randomized, double-blind, active- and placebo-controlled, parallel group, multicenter study assessing the safety and protective effect on the endometrium of 4 dosage combinations of norethindrone acetate plus ethinyl estradiol.

Poster presentation North American Menopause Society Meeting (NAMS)2000

Endometrial Protection Data Poster Presentation American Society of

Reproductive Medicine (ASRM) Orlando Fl 2000

Endometrial Hyperplasia and Proliferation in 2 pooled studies Abstract NAMS Chicago Il 2002

3rd World Congress on Controversies in Obstetrics and Gynecology 2002

-- Phase II double-blind placebo-controlled trial of the safety, toleration and efficacy of the SERM CP-336,156 for the prevention of bone loss in postmenopausal women.

-- Efficacy and Safety of an OCP in the Treatment of Moderate Acne Vulgaris - A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study.

Poster presentation American Society for Reproductive Medicine 3/2001

American Association of Nurse Practitioners 2001

Effects of Low Dose Oral Contraception in Weight in Women with Moderate Acne Vulgaris

Poster presentation 3rd World Congress in Obstetrics and Gynecology 2002

-- Phase II, Double-Blind, Placebo-Controlled Trial of the Safety, Toleration and Efficacy of a SERM and Raloxifene 60 mg/d for the Prevention of Bone Loss in Postmenopausal Women

Poster NAMS Washington DC 2004: Lasofoxifene, but not Raloxifene, has beneficial effects on markers of vaginal atrophy

--A Multicenter, Open Label Randomized, Crossover, Preference Study of Oral Alendronate Sodium 70 mg Once Weekly and 10 mg Once Daily in Postmenopausal Women with Osteoporosis.

Poster presentation NAMS, 2001

--A Phase III, Parallel, Randomized, Multicenter, Open Label Clinical Study to Evaluate the Efficacy and Safety of Extended Oral Contraceptive Therapy—84 Day Active Cycle

--Two year phase 3 extension study of extended-cycle OCs

-- Effects of Norethindrone Acetate (NA - 1 mg) Plus Ethinyl Estradiol (EE -10micrgm) in Perimenopausal Women: A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study

-- A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Effect of an investigational drug on Insulin and Ovarian Androgen Production in Obese Women with Polycystic Ovary Syndrome (PCOS).

Abstract ASRM 2001

- A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Effect of 500 and 1000mg of INS-1 on Ovulatory, endocrine and metabolic abnormalities in Obese Women with Polycystic Ovary Syndrome (PCOS).
- A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Effect of several doses of an investigational drug on Ovulatory, endocrine and metabolic abnormalities in Obese Women with Polycystic Ovary Syndrome (PCOS).
- Genomic Substudy in Women with Polycystic Ovary Syndrome
- A Randomized, Placebo-controlled, double-blind clinical study to assess the Effect of D-Chiro-Inositol on Clomiphene Citrate induced Ovulation in Women with Polycystic Ovary Syndrome
- A Randomized, Placebo-Controlled, Double-blind, Parallel-group
- Study of the Relative Clinical Efficacy of Two 6.5% Tioconazole Vaginal Ointment Products: A Bioequivalence Study.
- Double-Blind, Randomized, Multicenter, Parallel Group Study Comparing the Therapeutic Equivalence and Safety of Miconazole Nitrate 4% Vaginal Cream with Monistat-3 Cream in the Treatment of Vulvovaginal Candidiasis.
- Multicenter, Randomized, Double Blind, Placebo-Controlled, Safety and Efficacy Study of an OCP in Women with Dysmenorrhea.
- Beyond Endorsed Lipid Lowering with EBCT Scanning - Atorvastatin 80 mg vs Pravastatin 40 mg.
- A 20-Week, Open-Label Assessment of the Safety and Efficacy Profile of Atorvastatin when used to Optimally Control Dyslipidemia in Postmenopausal Patients.
- Impact of Progestogen Choice on Mood and the Quality of Life and Satisfaction of Women
- Dose Range Finding and Efficacy Study of Estradiol (E₂) Administration with a GnRH agonist in Premenopausal Women with Uterine Leiomyomata and Eligible for Hysterectomy.
- A Randomized, Open-Label, Comparative Trial of Bone Mineral Density, Cognition, and Quality of Life with Norethindrone Acetate (NA - 1 mg) Plus Ethinyl Estradiol (EE - 10 µg), Evista® (Raloxifene), and PremPro™ in Women 5 to 15 Years Postmenopausal.
Poster presentation ACOG New Orleans, LA 2002—Lack of Effect of Raloxifene on markers of bone turnover compared to EE/NETA combined CCHRT
- A 12-Week, Randomized, Partially-Blinded, Active and Placebo-Controlled, Multicenter Study Assessing the Effect of Norethindrone Acetate (NA - 1 mg) Plus Ethinyl Estradiol (EE -5 and 10 µg) on Endothelial Dysfunction in Postmenopausal Women.
- A Study of the Safety and Efficacy of a SERM for the Prevention of Bone Loss and for Lipid Lowering in Postmenopausal Women at Risk for Osteoporosis
- A Randomized, Double blind Multicenter Study Evaluating and Comparing the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women
- Phase I/II Randomized, Placebo-controlled Proof of Concept Study to Evaluate the Effects of a SERM in Combination with Estradiol on Vasomotor Symptoms in Postmenopausal Women
- Multicenter, Multinational, Randomized, Double-Blind, Active Controlled Comparative Trial to Assess the Histological Profile Endometrial and Breast Endpoints Following Treatment with Tibolone versus Conjugated Estrogen plus Medroxyprogesterone Acetate in Postmenopausal Women
- Double-blind, Placebo Controlled Dose Ranging Trial to Evaluate the Efficacy of Atorvastatin on Bone Mineral Density and Markers of Bone Turnover in Postmenopausal Women
- Phase IIIb, Multicenter Trial Comparison of injectable progestin contraception on bone mineral density
- Prospective, Randomized Double-blind Comparative Trial to Evaluate the efficacy and safety of Ciprofloxacin 500mg once daily extended release 3 days vs. Ciprofloxacin 250mg BID 3 days for uncomplicated UTI in women

- A 6 month Randomized, Placebo-Controlled Study of the Safety and Efficacy of Lasofoxifene in the Treatment of Vaginal Atrophy in Postmenopausal Women with assessment of short term effects on bone mineral density
 - Poster Presentation Vaginal Ph and MI changes with Lasofoxifene
 - ACOG Philadelphia 2004
 - Poster NAMS 2004 Washington DC: pH, MI effects of Lasofoxifene vs placebo
 - Poster NAMS 2004 Washington DC: Beneficial effects of Laso. vs placebo in patient reported symptom of irritation and burning
- A Phase III, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of 91 Day Cycle Combination Oral Contraceptive Regimens Utilizing Ethinyl Estradiol During the Pill-Free Interval for the Prevention of Pregnancy in Women
 - Oral Presentation Association of Reproductive Health Professionals (ARHP)
 - Annual Meeting, Tampa, FL 2005
 - Contraception* 72 (2005) pg 230
- Up to 3 year phase 3 extension of 91 Day Cycle Oral Contraception
 - Poster Presentation, ARHP Annual Meeting, Tampa, FL 2005
 - Contraception* 72 (2005) pg 238
- Phase II/III multi-center Randomized study of the safety and efficacy of topical Estradiol gel in the treatment of vasomotor symptoms in postmenopausal women
- A 6 month open label randomized multicenter study to evaluate the comparative efficacy and safety of oral anti-viral in the episodic and suppressive treatment of recurrent genital herpes
- A 12 week phase 3 Study of the efficacy and safety of a SERM in the treatment of vaginal atrophy in postmenopausal women
- Randomized Multicenter, Double-blind controlled study to compare the effectiveness of a single dose anti-viral and Placebo in patient-initiated episodic treatment of recurrent Herpes Labialis
- Open-label non-randomized trial of the symptom specific effectiveness of an anti-muscarinic in adult patients with symptoms of overactive bladder
- Phase III randomized, placebo-controlled multi-center study of efficacy and safety of a non-hormonal agent for the treatment of postmenopausal vasomotor symptoms
- A prospective, open label, multi-center phase IIIb study to investigate patient satisfaction with montly Ibisphophonate in women with postmenopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate.
- A prospective, randomized, parallel, double-blind controlled study of a multi-component medical food for the relief of breast pain associated with fibrocystic breast disease
- An open label multi-center study to determine level of adherence to monthly oral or every three month intravenous bisphosphonate treatment in postmenopausal women with osteoporosis or osteopenia who are GI intolerant of daily and/or weekly alendronate or risedronate
- A multi-center, double-blind, double-dummy, randomized, placebo-controlled study comparing a progestin-estradiol transdermal patch with a placebo patch in postmenopausal women to determine the lowest effective dose of estradiol for the relief of moderate to severe hot flushes
- A randomized, multi-center, double-blind study to evaluate the efficacy of an extended cycle combination oral contraceptive which utilizes ethinyl estradiol during the usual hormone-free interval, compared to conventional oral contraceptive therapy for the treatment of cyclic pelvic pain in women
- A randomized, multi-center, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens tablets for the treatment of vulvovaginal atrophy in healthy postmenopausal women
- A multi-center, double-phase, randomized, double-blind, placebo controlled (12-week double-blind followed by 12-week open label) study evaluating the effect of an anti-muscarinic on urgency urinary incontinence (UUI), urgency, frequency, sexual quality of life and sexual function in women with overactive bladder

- A prospective, open-label, multi-center extension study of a multi-component medical food for the relief of breast pain associated with fibrocystic breast disease
- Multi-Center Open-Label Phase III study to evaluate the efficacy and safety of an extended cycle low dose combination oral contraception regimen, which utilizes ethinyl estradiol during the hormone-free interval for the prevention of pregnancy in women
- Double-blind randomized, placebo- and active-controlled efficacy and safety study of a SERM/estrogen combination for the treatment of moderate to severe vulvar/vaginal atrophy in post-menopausal women
- Double-blind, randomized, parallel, placebo-controlled multicenter trial to compare the effects of 12 weeks of treatment with an estradiol vaginal cream, USP, 0.01% vs Estrace® vaginal cream on vulvovaginal atrophy in healthy postmenopausal women
- Randomized, multicenter, double-blind placebo-controlled trial to demonstrate the safety and efficacy of daily synthetic conjugated estrogens for the treatment of vasomotor symptoms in postmenopausal women
- A 24-week, Randomized, Double-Blind Placebo Controlled, Safety and Efficacy Trial of an investigational centrally-acting drug in Premenopausal Women with Hypoactive Sexual Desire Disorder
- A 12-week randomized, multicenter, double blind placebo-controlled study to compare the effects of an investigational estrogen cream to placebo on vulvovaginal atrophy
- Phase IIB multi-center double-blind dose-ranging study evaluating the safety and efficacy of a non-hormonal investigational medication for the treatment of severe vasomotor symptoms associated with menopause
- A prospective, multicenter, open-label study to evaluate the safety and efficacy of a 21 day active combined OC and 7 days EE oral contraceptive regimen
- Open label Study of the Safety and Efficacy of a New Low Dose Oral Contraceptive Containing Norethindrone Acetate 1 mg and Ethinyl Estradiol 10mcg with a 2 day hormone free-interval
- A Phase II randomized Double-Blind Active -Controlled Study to Assess the Bone Density Safety and Treatment Efficacy of an Investigational Oral GnRH antagonist in Subjects with Endometriosis
- A partial double-blind. Placebo-controlled study to assess the efficacy and safety of an aromatase inhibitor on endometrial thickness in healthy premenopausal women when dosed at various times during the menstrual cycle
- A multicenter, open-Label Study to evaluate the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of Nestorone and Ethinyl Estradiol
- Multi-center open-labeled randomized study to assess the safety and contraceptive efficacy of two doses of the ultra low dose contraceptive intrauterine system for a maximum of 3 years in women 18 to 35 years of age
- A multicenter, double-blind randomized placebo-controlled study to determine the lowest effective dose of an oral progestin and 17beta estradiol for the relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks
- A prospective multicenter randomized double-blind study to evaluate hormone patterns and ovarian follicular with the oral contraceptive
- A phase III randomized double-blind placebo controlled multicenter study to determine the safety and efficacy of an investigational treatment for obesity in adults with BMI ≥ 35
- A phase III randomized double-blind placebo controlled multicenter study to determine the safety and efficacy of an investigational treatment for obesity in adults with obesity-related co-morbid conditions
- Phase II 12 week randomized double blind placebo controlled multicenter study of the efficacy and safety of a SERM in the treatment of severe vaginal dryness and vaginal pain associated with sexual activity, symptoms of vulvar and vaginal atrophy associated with menopause
- A 6 month phase III multicenter randomized double-blind placebo-controlled study to investigate the safety and efficacy of an extended release non-hormonal tablet in the treatment of vasomotor symptoms in post-menopausal women

- A multicenter, randomized double-blind active-controlled parallel group 2-arm study to show superiority of an oral contraceptive over Ortho Tri-Cyclen Lo on hormone withdrawal-associated symptoms after 6 cycles of treatment
- A randomized, double-blind placebo-controlled dose-ranging multicenter evaluation of a topically administered medication versus placebo in subjects with pain associated with fibrocystic breast disease
- Psychometric evaluation and validation of the symptoms of an endometriosis scale in electronic diary format
- A Phase 2, 16 week multicenter, randomized double blind placebo controlled, parallel group proof of concept study evaluating the safety and efficacy of an IgG2 monoclonal antibody directed against nerve growth factor for the treatment of pain associated with endometriosis
- Multicenter, open-label uncontrolled study to investigate the efficacy and safety of a transdermal contraceptive patch in a 21-day regimen for 13 cycles in healthy female subjects
- A 3 month Phase 3 multicenter randomized double-blind placebo controlled study to investigate the safety and efficacy of an extended release non-hormonal treatment of vasomotor symptoms in postmenopausal women
- Double blind randomized placebo and active controlled efficacy and safety study of the effects of SERM/estrogen combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women
- Phase III multicenter randomized placebo controlled trial investigating the safety and efficacy of a centrally acting drug for the treatment of HSDD in pre-menopausal women
- Phase III multicenter randomized placebo controlled trial investigating the safety and efficacy of a centrally acting drug for the treatment of HSDD in post-menopausal women
- Multicenter open label single arm safety and efficacy pregnancy prevention trial of an extended cycle dose escalating oral combined contraceptive
- Phase III randomized multicenter placebo controlled trial of vaginal DHEA in the treatment of postmenopausal vaginal atrophy
- Phase III 6 month double-blind placebo controlled trial non-hormonal treatment using extended-release gabapentin for the treatment of post-menopausal vasomotor symptoms

Journal Articles/Presentations

- Review--HRT and The Human Genome Project: Trends In Formulation and Dose
The Female Patient Dec. 2001
- Endometrial Protection with Norethindrone Acetate in CCHRT *American Journal of Ob/Gyn* FEB 2003
- A Review of Current Recommendations for Hormone Therapy 2006 *American Family Physician, American Journal for Nurse Practitioners*
- Hormone Therapy Update: Current Recommendations for Menopausal Symptoms, *US Pharmacist* 2006
- A Review of Current Recommendations for Hormone Therapy 8/2006
Current Women's Health Reviews
- Long-term Safety of an Extended-regimen Oral Contraceptive (Seasonale): a Two-year Multicenter Open-Label Extension Trial *American Journal of Ob/Gyn* July 2006
- Safety and Efficacy of Extended Regimen Oral Contraception Utilizing Continuous Low-Dose Ethinyl Estradiol *Contraception* 2006;73:229-234
- A One-Year Safety and Efficacy Trial of a low-dose extended cycle birth control regimen (Seasonale Lo®) and a Two-Year open label extension study of Seasonale Lo® *Ob/Gyn* April 2006 supplement (abstracts)
- Treatment Duration and Adherence to Vaginal Estrogen Therapy in Patients Receiving Vaginal Tablets versus Vaginal Creams in a Managed Care Setting. In Press 2008
Journal of Women's Health

The Development of the Menopause Impact Tool. Supplement to *Contemporary Ob/Gyn* July 2006
The Development of the Menopause Impact Tool, Poster Presentation Annual Meeting of *The North American Menopause Society*, Nashville September 2006
A New Office-Based Menopause Assessment Questionnaire, Poster Presentation Annual Meeting of *The North American Menopause Society*, Nashville September 2006
Altering the Hormone-Free Interval with Extended-Cycle Contraception, *The Female Patient* September 2006 Supplement
Reproductive Dysfunction for Women with Epilepsy: Update and Directions for Research, Submitted *Epilepsy and Behavior* August 2007
Ospemifene Improves the Clinical Signs of Vaginal Atrophy: Results from a Pivotal Phase 3 Study Poster Presentation *NAMS Orlando FL 2008*
The effectiveness of twice-weekly synthetic conjugated estrogens B on seven investigator-assessed clinical signs of vaginal atrophy Poster *NAMS Orlando 2008*
A comparison of Extended Cycle Oral contraception and Cyclic OCs for the treatment of cyclic pelvic pain Oral Presentation *ASRM San Francisco 2008*
Medication Adherence to Vaginal Estrogen Therapy: Implications for Clinical Practice *Journal of Women's Health* May 2008 17(4):569-578
Adding low-dose estrogen to the hormone free interval: Impact on bleeding patterns on Bleeding patterns in users of a 91-day regimen oral contraception *Contraception* 2009 79; 350-355

SOCIETIES

Fellow, American College of Ob/Gyn
Diplomat, American Board of Ob/Gyn
Member, North American Menopause Society
Member, International Menopause Society
Member, Association of Reproductive Health Professionals
Member, International Society for the Study of Women's Sexual Health

STATE MEDICAL BOARD OF OHIO

30 E. Broad St., 3rd Floor, Columbus, Ohio 43215-6127

www.med.ohio.gov

EXPIRES : 04/01/2012

LICENSE NUMBER

35 . 062718



Dr. DAVID JAY PORTMAN

Doctor of Medicine

*is duly registered and entitled to practice in The State of Ohio
until the expiration date.*

AUDIT # : 32168

**As a physician or podiatrist practicing in the State
of Ohio, you are responsible for:**

- *Keeping informed of new laws and rules pertaining to your profession.*
- *Reporting any violations of the Medical Practices Act to our complaint hotline at 1-800-554-7717.*
- *Notifying the board in writing within 30 days of any change in your address - (residence and principal practice)*
- *Completing and maintaining documentation of CME.*

Access website at www.med.ohio.gov to obtain current information from the board.

A handwritten signature in cursive script, appearing to read "David Jay Portman".

Signature